Alkermes stock drops 6.5% after FDA briefing documents raise questions about depression drug - MarketWatch

Alkermes stock drops 6.5% after FDA briefing documents raise questions about depression drugMarketWatchThe drug is intended for major depressive disorder, also called depression, which affects an estimated one in 15 adults in any given year, according to the American Psychiatric Association. ALKS 5461 is intended for those who haven't had a good-enough ...and more »